Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Acn Research LLC

Neither a doctor nor a teaching hospital

Research payments

$562,503

100 payments

Through program year 2025, Acn Research LLC is reported as receiving $562,503 in research payments, across 100 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,518 2
2024 Research $7,544 2
2023 Research $19,363 2
2022 Research $14,667 2
2021 Research $12,915 4
2020 Research $171,004 19
2019 Research $334,491 69

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $207,801 46 payments
  2. Eli Lilly and Company $198,676 19 payments
  3. GlaxoSmithKline, LLC. $84,408 9 payments
  4. Regeneron Pharmaceuticals, Inc. $71,618 26 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $199,327 43 payments
  2. A Multicenter Long-Term Extension Study of 104 Weeks Including A Double Blind Placebo Controlled 40 Week Randomized Withdrawal Retreatment Period to Evaluate the Maintenance of Treatment Effect of Ixekizumab Ly2439821 in Patients With Axial Spondyloarthritis $74,807 2 payments
  3. A Randomized, Active-Controlled, Parallel-Group, Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $74,573 8 payments
  4. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $68,311 24 payments
  5. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $67,218 5 payments
  6. A Randomized Active-Controlled Parallel-Group Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $19,322 1 payment
  7. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $17,190 4 payments
  8. A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3819469 $16,313 2 payments
  9. A Longterm Openlabel Extension Study of Tofacitinib Cp690550 for the Treatment of Psoriatic Arthritis $8,474 3 payments
  10. A 52 Week Multicenter Randomized Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab Ly2439821 in Bdmard Naive Patients With Nonradiographic Axial Spondyloarthritis $5,360 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record